Biotech Investors: Mark Your 2005 Calendars
Cypress BioScience (CYPB): Milnacipran, fibromyalgia phase III, third quarter 2005;
Genentech (DNA): Lucentis, age-related macular degeneration phase IIII, third quarter 2005. Avastin, front-line lung cancer phase III, second half 2005;
Allos Therapeutics (ALTH): Efaproxyn, brain metastases from lung cancer phase III, fourth quarter 2005;Telik (TELK): Telcyta, ovarian non-small-cell lung cancer phase III, fourth quarter 2005; Dendreon (DNDN): Provenge, prostate cancer phase III, second half/fourth quarter 2005; Pharmacyclics (PCYC): Xcytrin, brain metastases from lung cancer phase III, second half 2005. Northfield Laboratories (NFLD): Polyheme, blood substitute trauma phase III, year-end 2005; CancerVax (CNVX): Canvaxin, melanoma phase III, end of 2005.
Turning the PageOn a calendar note of a personal sort, today marks my last day at TheStreet.com. After four wonderful years here and 15 years as a business journalist, it's time for a new challenge. Next week, I'll be joining a New York-based investment firm as a biotech analyst (I'll remain on the West Coast.) I've been writing about biotech investing for a long time, so now's my chance to see if I can actually invest in biotech -- and make money doing it. I'm excited to start the new gig, but I leave TheStreet.com with some reluctance, because this has been (and continues to be) a great place to work and learn. I look back over the past four years and I marvel at how much I've learned about the way Wall Street really works. My investment education only accelerated when I was fortunate to join the staff of RealMoney two years ago. Thanks to Jim Cramer, Dave Morrow, the entire cast of RealMoney contributors and all the writers and editors at TheStreet. It's been a great ride. Finally, thanks to all my readers! Your constant feedback -- both naughty and nice -- kept me constantly energized and on my toes. I met some amazingly smart and friendly people through this Web site, readers who became trusted sources and helped me appear smarter than I am. I'm thankful and better for it, and will miss that part of the job more than anything. Next week, I stop watching and start doing. I can't wait to get started. Thanks again, and continued success to all.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV